These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19479704)

  • 21. The Impact Of Medicare's Mental Health Cost-Sharing Parity On Use Of Mental Health Care Services.
    Cook BL; Flores M; Zuvekas SH; Newhouse JP; Hsu J; Sonik R; Lee E; Fung V
    Health Aff (Millwood); 2020 May; 39(5):819-827. PubMed ID: 32364860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to an optimal treatment. Current situation.
    Ugarte-Gil MF; Silvestre AM; Pons-Estel BA
    Clin Rheumatol; 2015 Mar; 34 Suppl 1(Suppl 1):S59-66. PubMed ID: 26188617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elimination of Cost Sharing for Screening Mammography in Medicare Advantage Plans.
    Trivedi AN; Leyva B; Lee Y; Panagiotou OA; Dahabreh IJ
    N Engl J Med; 2018 Jan; 378(3):262-269. PubMed ID: 29342379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New challenges to medicare beneficiary access to mAbs.
    Cohen J; Wilson A
    MAbs; 2009; 1(1):56-66. PubMed ID: 20046575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Options for change under Medicare: impact of a cap on catastrophic illness expense.
    Gornick M; Beebe J; Prihoda R
    Health Care Financ Rev; 1983; 5(1):33-43. PubMed ID: 10310275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D.
    Jung JK; Feldman R; McBean AM
    Forum Health Econ Policy; 2017 Dec; 20(2):. PubMed ID: 29610565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prior Authorization and Association With Delayed or Discontinued Prescription Fills.
    Kyle MA; Keating NL
    J Clin Oncol; 2024 Mar; 42(8):951-960. PubMed ID: 38086013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in Permanent Work Disability Associated With Rheumatoid Arthritis in the United States, 1999-2015.
    Ward MM
    Arthritis Care Res (Hoboken); 2022 Aug; 74(8):1321-1324. PubMed ID: 33544975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Employer-Sponsored Medicare Advantage Plans and the 2018 Therapy Cap Repeal: Reduced Overall Spending Does Not Constrain Out-of-Pocket Costs.
    Fahmy JN; Kong L; Wang L; Chung KC
    Ann Plast Surg; 2024 Aug; ():. PubMed ID: 39150791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Savings for Medicare Part D Beneficiaries Using a Direct-to-Consumer Model.
    Berkowitz ST; Groth S; Sternberg P; Patel S
    Ophthalmology; 2024 Apr; 131(4):509-510. PubMed ID: 38072014
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparing Medicare plan selection among beneficiaries with and without a history of cancer.
    Jazowski SA; Achola EM; Nicholas LH; Wood WA; Friese CR; Dusetzina SB
    Health Aff Sch; 2024 Feb; 2(2):qxae014. PubMed ID: 38756548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D.
    Einav L; Finkelstein A; Polyakova M
    Am Econ J Econ Policy; 2018 Aug; 10(3):122-153. PubMed ID: 30233766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Unintended Consequences of Medicare Observation Status.
    Goldstein JN
    Dela J Public Health; 2019 Dec; 5(5):26-28. PubMed ID: 34467067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Part D Formulary and Benefit Design as a Risk-Steering Mechanism.
    Goldman DP; Joyce GF; Vogt WB
    Am Econ Rev; 2011 May; 101(3):382-386. PubMed ID: 25067840
    [No Abstract]   [Full Text] [Related]  

  • 35. The Unintended Cost of High Cost Sharing in Medicare-Assessing Consequences for Patients and Options for Policy.
    Roberts ET
    JAMA Health Forum; 2021 Dec; 2(12):. PubMed ID: 35024690
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D.
    Tseng CW; Masuda C; Chen R; Hartung DM
    Diabetes Care; 2020 Apr; 43(4):e50-e51. PubMed ID: 32041898
    [No Abstract]   [Full Text] [Related]  

  • 37. Copay accumulators: Shifting costs of oncology drugs from plans to patients.
    Baker KP; Mullangi S
    Cancer; 2024 Jun; ():. PubMed ID: 38924522
    [No Abstract]   [Full Text] [Related]  

  • 38. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
    Zhang J; Xie F; Delzell E; Chen L; Kilgore ML; Yun H; Saag KG; Lewis JD; Curtis JR
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1743-51. PubMed ID: 23754804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
    Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
    Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.